Skip to Main Content

Paper Details

Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial.
Eur J Cancer
1
2023
Afatinib, CLIP2, EGFR, ErbB, ErbB-dysregulated tumours, HER2, Patients, afatinib, cancer, glioneuronal tumour, paediatric, paediatric cancers, patient, patients, tumours
Author NameAffiliation
Lynley V MarshallThe Royal Marsden NHS Foundation Trust and The Institute of Cancer Research
Eric BouffetThe Hospital for Sick Children, University of Toronto
David S ZieglerKids Cancer Centre, Sydney Children's Hospital, Australia School of Clinical Medicine, Australia Children's Cancer Institute, University of New South Wales
  • 1 - 3

Datasets

Release 1.2